Search

Displaying results 3371 - 3380 of 10000 in total
  1. Drug

    Propiolactone

    go.drugbank.com/drugs/DB09348
    ApprovedWithdrawn

    [A32144] It is currently FDA approved for its use as an indirect additive used in food contact substances. Propiolactone was first commercially available in the United States in 1958.[A32144]

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    DAS-431 IV

    go.drugbank.com/drugs/DB05432
    Experimental

    DAS-431 IV is a dopamine D1 receptor agonist developed by DrugAbuse Sciences for the treatment of Addictions, Schizophrenia, Schizoaffective Disorders, Dementia, Parkinson's Disease, Strokes etc.

  3. Drug

    Human papillomavirus type 31 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10310
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 31. … Human papillomavirus type 31 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection.

    Mixtures: GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO, GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO
  4. Drug

    Maropitant

    go.drugbank.com/drugs/DB11427
    ExperimentalVet approved

    It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats. … Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs.

  5. Drug

    MM-111

    go.drugbank.com/drugs/DB17983
    Investigational

    MM-111 is a novel bispecific antibody fusion protein that co-targets the the epidermal growth factor family receptor tyrosine kinases, ERBB2 and ERBB3.

  6. Drug

    PSN9301

    go.drugbank.com/drugs/DB05001
    Experimental

    PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.

  7. Drug

    Human papillomavirus type 33 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10311
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 33. … Human papillomavirus type 33 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection.

    Mixtures: GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO, GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO
  8. Drug

    Human papillomavirus type 45 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10312
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 45. … Human papillomavirus type 45 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection.

    Mixtures: GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO, GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO
  9. Drug

    Human papillomavirus type 58 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10314
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 58. … Human papillomavirus type 58 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection.

    Mixtures: GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO, GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO
  10. Drug

    TGAAC94

    go.drugbank.com/drugs/DB06175
    Investigational

    It was under investigation in clinical trials to treat Inflammatory Arthritis. In 2007, one patient participating in the clinical trial died and the trial was placed on clinical hold by the FDA. … The Health Recombinant DNA Advisory Committee (RAC) concluded that a possible role of the gene transfer in this clinical course could not definitively be excluded due to the lack of data. [A264038]